Tekla Life Sciences Investors

HQL

$20.71

-1.29%

N/A-$0.27

Financial Services

Asset Management

NYSE

Active Trading

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced ...

Financial Highlights of HQL

Profitability trend

Latest / TTM · 6 periods

Gross Margin

90.7%

Net Margin

331.9%

P/E Ratio

3.07x

n/a

Debt / Equity

0.00

n/a

Current Ratio

2.58

Dividend Yield

10.8%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

90.7%

Net Margin

331.9%

P/E Ratio

3.07x

Debt / Equity

0.00

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	86.5%	82.6%	46.4%	100.0%	100.0%	—
Operating MarginOperating income as a percentage of revenue.	143.3%	-328.3%	-13.3%	98.4%	99.1%	—
Net MarginNet income as a percentage of revenue.	143.3%	-328.3%	56.8%	98.4%	99.1%	—
EBITDA MarginEBITDA divided by revenue.	152.5%	-318.9%	126.8%	100.6%	99.1%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	143.3%	-328.3%	56.8%	98.4%	99.1%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	0.01	0.12	0.00	0.32	1.74	—
Quick RatioLiquid assets divided by current liabilities.	0.01	0.12	0.00	0.32	1.74	—
Cash RatioCash and equivalents divided by current liabilities.	0.00	0.00	0.00	0.00	0.10	—
Debt / AssetsDebt as a share of total assets.	0.3%	2.7%	0.0%	0.0%	0.0%	—
Debt / EquityDebt compared with shareholder equity.	0.00	0.03	0.00	0.00	0.00	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	299.48x	51.10x	7.81x	375.09x	75.90x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	40.42x	1.09x	0.00x	2991.21x	6.90x	—
Asset TurnoverRevenue generated per dollar of assets.	0.08x	0.08x	0.10x	0.19x	0.17x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	-8.11x	-4.23x	138.36x	39.06x	-2291.28x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	7.82x	-3.36x	15.78x	4.96x	5.24x	—
P/B RatioPrice paid for each dollar of book value.	0.96x	0.88x	0.88x	0.92x	0.87x	—
P/S RatioPrice paid for each dollar of sales.	11.21x	11.01x	8.96x	4.88x	5.18x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	0.00x	0.00x	0.00x	0.00x	-193.00x	—
Dividend YieldAnnual dividend divided by current share price.	8.1%	10.8%	10.3%	11.0%	7.1%	—

Upstream

abrdn Inc.UnconfirmedState Street Bank and Trust CompanyNYSE:STTKPMG LLPAberdeen Fund Distributors, LLCDestra Capital Advisors LLCAberdeen Group plc (formerly abrdn plc)LSE:ABDNAmgen Inc.NASDAQ:AMGN Regeneron Pharmaceuticals Inc.NASDAQ:REGN Insmed Inc.NASDAQ:INSM uniQure NVNASDAQ:QURE Vaxcyte Inc.NASDAQ:PCVX argenx SE ADRNASDAQ:ARGX Veradermics Inc.NASDAQ:MANE Dyne Therapeutics Inc.NASDAQ:DYN Denali Therapeutics Inc.NASDAQ:DNLI Crinetics Pharmaceuticals Inc.NASDAQ:CRNX

Downstream

New York Stock Exchange (NYSE)NYSE:ICEAberdeen Fund Distributors, LLCDestra Capital Advisors LLCFirst Trust Advisors LPSaba Capital Management, L.P.Penserra Capital Management LLCAmplify Investments LLCRaymond James Financial, Inc.NYSE:RJFRetail Shareholders (via brokerage platforms: Schwab, Fidelity, E*Trade, Public.com, etc.)

Proxies

abrdn Healthcare InvestorsNYSE:HQH abrdn Healthcare Opportunities FundNYSE:THQ abrdn World Healthcare FundNYSE:THWAberdeen Group plcLSE:ABDNiShares Biotechnology ETFNASDAQ:IBB

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Tekla Life Sciences Investors

Financial Highlights of HQL

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of HQL

Upstream

Downstream

Proxies

Financial Highlights of HQL

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of HQL

Upstream

Downstream

Proxies